Servier bags an antibody specialist in its latest oncology M&A deal with plans to add the platform tech
Whatever Servier learned about Symphogen during their 2-year development alliance must have significantly whetted their appetite for an acquisition.
Paris-based Servier announced Friday that it has struck a deal to buy out the antibody expert. The acquisition comes 2 years after Servier acquired Shire’s cancer business for $2.4 billion. They’ve been working with Symphogen on a slate of programs, including some favs – PD-1, LAG3 and TIM3 — where they are looking to differentiate themselves from the more prominent drugs in these niches.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 117,900+ biopharma pros reading Endpoints daily — and it's free.